Matching articles for "fezolinetant"
Issue 1744 · December 22, 2025
Elinzanetant (Lynkuet) for Menopausal Vasomotor Symptoms

Elinzanetant ( Lynkuet – Bayer), a first-in-class neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist, has been approved by the FDA for treatment of moderate to severe vasomotor symptoms (VMS) due…

Med Lett Drugs Ther. 2025 Dec 22; 67(1744):203-6 doi:10.58347/tml.2025.1744b
Elinzanetant ( Lynkuet – Bayer), a first-in-class neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist, has been approved by the FDA for treatment of moderate to severe vasomotor symptoms (VMS) due to menopause. Fezolinetant (Veozah) , an NK3 receptor antagonist, was approved for the same indication in 2023.
Issue 1713 · October 14, 2024 Free
In Brief: New Warning for Fezolinetant (Veozah)

The FDA has required a new warning in the label of the oral selective neurokinin 3 (NK3) receptor antagonist fezolinetant (Veozah) about the risk of hepatoxicity. The label of fezolinetant, which was approved…

Med Lett Drugs Ther. 2024 Oct 14; 66(1713):168 doi:10.58347/tml.2024.1713e
The FDA has required a new warning in the label of the oral selective neurokinin 3 (NK3) receptor antagonist fezolinetant (Veozah) about the risk of hepatoxicity. The label of fezolinetant, which was approved by the FDA in 2023 for treatment of moderate to severe vasomotor symptoms due to menopause, already contained a warning about hepatic transaminase elevations associated with use of the drug.
Issue 1697 · March 4, 2024
Drugs for Menopausal Symptoms

The primary symptoms of menopause are genitourinary and vasomotor. The genitourinary syndrome of menopause (GSM) includes symptoms such as burning, irritation, dryness, dyspareunia, dysuria, and recurrent…

Med Lett Drugs Ther. 2024 Mar 4; 66(1697):33-8 doi:10.58347/tml.2024.1697a
The primary symptoms of menopause are genitourinary and vasomotor. The genitourinary syndrome of menopause (GSM) includes symptoms such as burning, irritation, dryness, dyspareunia, dysuria, and recurrent urinary tract infection. Vasomotor symptoms (VMS; hot flashes, night sweats) often disrupt sleep.
Issue 1679 · June 26, 2023
Fezolinetant (Veozah) for Menopausal Vasomotor Symptoms

Fezolinetant ( Veozah – Astellas), a first-in-class neurokinin 3 (NK3) receptor antagonist, has been approved by the FDA for treatment of moderate to severe vasomotor symptoms (VMS) due to menopause. It is…

Med Lett Drugs Ther. 2023 Jun 26; 65(1679):97-9 doi:10.58347/tml.2023.1679a
Fezolinetant ( Veozah – Astellas), a first-in-class neurokinin 3 (NK3) receptor antagonist, has been approved by the FDA for treatment of moderate to severe vasomotor symptoms (VMS) due to menopause. It is the second nonhormonal treatment to be approved in the US for this indication; a low-dose formulation of the selective serotonin reuptake inhibitor (SSRI) paroxetine mesylate (Brisdelle) was approved in 2013.